{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T01:10:51Z","timestamp":1747185051428,"version":"3.40.5"},"reference-count":33,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Treatment optimization in haemophilia A can be achieved by choice of FVIII product and knowledge of pharmacokinetics (PK), phenotype and adherence. A favourable PK profile of BAY 81\u20138973 (octocog alfa) (Kovaltry, Bayer AB) compared to other standard half\u2010life (SHL) FVIII products has been suggested.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluate whether the switch to BAY 81\u20138973, using the same dosing schedule, impact factor consumption and bleed rates, taking arthropathy and adherence into account<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Forty patients on prophylaxis with SHL (median age 40.5 years) attending the haemophilia treatment centres in Malm\u00f6 and Oslo were enrolled. The annualised bleeding rate (ABR) and joint bleeding rate (AJBR) before and after the switch to BAY 81\u20138973 was calculated. PK analyses were performed with WAPPS\u2010Hemo. Joint health status and treatment adherence were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median ABR and AJBR was 0 before and after the switch, at both centres. The median yearly factor consumption was 3,345 IU\/Kg\/year in the entire study group corresponding to intermediate\u2010intensity prophylaxis in most patients and with significantly more used in Malm\u00f6 (3,862 IU\/Kg\/year), compared to Oslo (2,337 IU\/Kg\/year) (<jats:italic>P<\/jats:italic> .006). There was no correlation between arthropathy and bleeding. The median BAY 81\u20138973 t\u00bd was 15.15\u00a0h (range 7.5\u201329\u00a0h), with significant correlation to VWF levels, and 13.4\u00a0h after exclusion of VWF outliers. Adherence to treatment was 97%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Concentrate switch, using mainly intermediate\u2010intensity regimens with high adherence rates, preserves excellent prophylaxis outcome using standard half\u2010life FVIII products, indicating the value of individualized prophylaxis and close follow\u2010up.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.14489","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T10:42:12Z","timestamp":1641811332000},"page":"223-229","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical outcome and adherence rate in Scandinavian patients with intermediate\u2010intensity prophylaxis before and after the switch of standard half\u2010life FVIII products to BAY 81\u20138973"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9371-9396","authenticated-orcid":false,"given":"Alexandros","family":"Arvanitakis","sequence":"first","affiliation":[{"name":"Department of Translational Medicine Lund University  Malm\u00f6 Sweden"},{"name":"Department of Haematology Oncology and Radiation Physics Sk\u00e5ne University Hospital  Malm\u00f6 Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e5l Andre","family":"Holme","sequence":"additional","affiliation":[{"name":"Department of Haematology Oslo University Hospital  Oslo Norway"},{"name":"Institute of Clinical Medicine University of Oslo  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2888-4931","authenticated-orcid":false,"given":"Erik","family":"Berntorp","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine Lund University  Malm\u00f6 Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8500-2483","authenticated-orcid":false,"given":"Jan","family":"Astermark","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine Lund University  Malm\u00f6 Sweden"},{"name":"Department of Haematology Oncology and Radiation Physics Sk\u00e5ne University Hospital  Malm\u00f6 Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61139-2"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01463.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1992.tb00546.x"},{"issue":"5","key":"e_1_2_9_5_1","first-page":"555","article-title":"Anti\u2010hemophilic factor (recombinant), plasma\/albumin\u2010free method (octocog\u2010alpha; ADVATE) in the management of hemophilia A","volume":"3","author":"Shapiro AD","year":"2007","journal-title":"Vasc Health Risk Manage"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-009-0435-x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01420.x"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-016-0191-4"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13438"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12691"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0492-2"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03703.x"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.2196\/resprot.6558"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.595"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12055"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1993.tb00638.x"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1997.00091.x"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.15256\/joc.2011.1.2"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02423.x"},{"issue":"343","key":"e_1_2_9_20_1","first-page":"6","article-title":"Pathogenesis, early diagnosis, and prophylaxis for chronic hemophilic synovitis","author":"Rodr\u00edguez\u2010Merch\u00e1n EC","year":"1997","journal-title":"Clin Orthop Relat Res"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13449"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12533"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00952.x"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_2_9_25_1","unstructured":"AntovicJ Nordic Hemophilia Guidelines.2020."},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12592"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20353"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.168617"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-470898"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02129.x"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13003"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13867"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12985"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12301"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14489","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.14489","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T15:42:53Z","timestamp":1692978173000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.14489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1111\/hae.14489"],"URL":"https:\/\/doi.org\/10.1111\/hae.14489","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"type":"print","value":"1351-8216"},{"type":"electronic","value":"1365-2516"}],"subject":[],"published":{"date-parts":[[2022,1,10]]},"assertion":[{"value":"2021-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}